1Hatch GN.Rosuvastatin.Current opinion in cardiovascular, pulmonary and renal investigation[].Drugs.2000
2Graul A,Castaner J.ZD-4522.Hypolipidemic, HMG-CoA reductase inhibitor[].Drugs of the Future.1999
3Olsson A,Pears J,Mckellar J,et al.Effect of rosuvastatin on Low-density lipoprotein cholesterol in patients with hypercholesterolemioa[].The American Journal of Cardiology.2001
4Davidson M,Ma P,Stein E,et al.Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type lla or llb hypercholesterolemia[].The American Journal of Cardiology.2002
5Knopp RH.Drug treatment of lipid disorders[].The New England Journal of Medicine.1999
6Watanabe M,Koike H,Ishiba T,et al.Synthesis and biological activity of methanesulfonamide pyrimidine-and N-methanesulfonyl pyrole-substi tuted 3,5-dihydroxy-6-heptenoates, a novel series of HMGCoA reductase inhibitors[].Bioorganic and Medicinal Chemistry.1997
8Martin PD,Dane AL,Nwose D,et al.No effect of age and gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor[].Journal of Clinical Pharmacology.2002
同被引文献7
1叶任高.内科学·第5版[M].北京：人民卫生出版社,2001.398-409.
2Hisatome I.Impact of serum uric acid level on the cardiovascu-lar system as a risk factor [J].Nihon Yakuriqaku Zasshi,2010,136(6): 325-329.
3Ichida K.Hyperuricemia and metabolic syndrome[J].Folia Pharmacol Jap,2010,136(6):321-324.
4Muntner P, He J,Astor BC,et al.Traditional and nontraditional riskfactors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study [J].J Am Soc Nephrol,2005,16(2):529-538.
